GLP1R and chronic kidney disease: Clinical evidence from studies on diabetic CKD suggests that GLP-1 RAs not only improve glycemic control and reduce CV risk but also slow the progression of CKD through reduction in albuminuria, reduced systemic inflammation, enhanced endothelial function, and weight loss [37, 48].